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Abstract
Background: There are neither sensitive nor specific laboratory tests for measuring disease
activity in localized scleroderma (LS). Monitoring is done almost exclusively by clinical assessment.
Our aim was to determine whether serum concentrations of TGFβ1 are a good biomarker of
disease activity in children with LS.
Methods: 55 pediatric patients with LS were divided into sub-types according to their main lesion;
morphea, generalized morphea, linear scleoderma affecting a limb or the face. The lesions were
further categorized by overall clinical assessment into active, inactive, and indeterminate groups
according to disease activity. Serum TGFβ1 concentration levels were measured by enzyme linked
immunosorbent assay (ELISA), analyzed and correlated with disease subtypes and disease activity.
Results: The mean TGFβ1 concentration were significantly higher in the patient group (51393 ±
33953 pg/ml) than in the control group (9825 ± 5287 pg/ml) (P < 0.001). The mean concentration
were elevated in all the disease subtypes, and did not correlate with disease duration or activity.
Conclusion: Serum concentration of TGFβ1 were elevated in patients with all subtypes of LS
irrespective of clinical disease activity. Although TGFβ1 may play an important role in the
pathogenesis of local skin fibrosis, circulating blood levels of molecules known to act locally may
not be useful biomarkers of disease activity.
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Background
Localized scleroderma (LS) is the most common type of
scleroderma in children. LS differs from systemic sclerosis
(SSc) by typically being confined to the skin and subcuta-
neous tissue, with only rare involvement of the internal
organs [1,2]. There are neither sensitive nor specific labo-
ratory tests for measuring disease activity, and monitoring
is done almost exclusively by clinical assessment, which is
often challenging. Identifying a laboratory marker of dis-
ease activity will aid in the management of affected chil-
dren.
The pathogenesis of the skin fibrosis is far from clear; like
other autoimmune diseases it is thought to involve an
environmental trigger in an immuno-susceptible host
leading to inflammation and damage, with increased pro-
duction and deposition of collagen [3]. The Transforming
Growth Factor β family of cytokines (TGFβ) plays a major
role in modulation of the immune response, and is a crit-
ical counter-inflammatory/regulatory cytokine. TGFβ1 is
also a central mediator in fibrosis and angiogenesis, play-
ing an important role in the fibrotic process in sclero-
derma [3]. Several studies have found elevated serum
TGFβ1 concentrations in both generalized and localized
forms of sclerosis [4-6]. Skin TGFβ1 levels are more diffi-
cult to quantitate and in one study, no differences were
found in affected skin from those with SSC [6] or LS [7].
Our study objectives were to determine the peripheral
blood levels of TGFβ1 in children with LS and to deter-
mine the relationship of serum levels to disease activity.
Patients and methods
Patients
Serum samples were collected and cryo preserved from 55
patients who were evaluated at the LS clinic at The Hospital
for Sick Children in Toronto. LS was diagnosed independ-
ently by both a board certified pediatric rheumatologist
and a pediatric dermatologis, who run the multi-discipli-
nary clinic together. A consensus regarding diagnosis, dis-
ease subtype, and disease activity was jointly made. All
clinical data were reviewed retrospectively from the
patients' chart records. The patients were divided into four
clinical subtypes according to their main lesion: Morphea
(M), generalized morphea (GM) when they had a large
area of the body involved and confluent or multiple mor-
pheic lesions (3 or more lesions), or a linear band with 2
or more lesions, and linear scleroderma (LIN) on a limb
(LIN limb) or on the face (LIN face "en coup de sabre").
The patients were further grouped according to their dis-
ease activity status which was determined clinically [1].
"Active phase" of LS was defined as lesions growing in
size, appearance of new lesions, or erythematous viola-
ceous color; "non-active phase" as no new lesions and no
change in size of previous lesions over a minimum 6
month period, "indeterminate" as those in whom it was
unclear and difficult to determine clinically whether there
was active skin inflammation or change from previous
visit. Informed consent was obtained for study participa-
tion and the institutional Research Ethics Board approved
the study.
Assays for TGFβ1
Following informed consent, serum samples were taken at
the time of clinical assessment. All samples were collected
and processed within 1 hour of collection, aliquoted, and
frozen at -800°C until time of assay. All samples were
tested at the same time, and triplicate samples were run.
Serum concentration of TGFβ1 (latent and active forms)
were measured by enzyme linked immunosorbent assay
(ELISA) (Medicorp, Montreal, Canada) according to man-
ufacturer's protocol. Our laboratory control population
consisted of randomly selected, age matched patients with
atopic dermatitis, a non-fibrotic inflammatory skin condi-
tion selected as a specificity control, attending a concur-
rent dermatology clinic.
Statistical analysis
Groups were compared for TGFβ1 serum concentrations
using student t-test (for 2 group comparisons). Analysis of
variance (ANOVA) was used when comparing 3 or more
groups. Analyses were repeated using non-parametric sta-
tistics (Mann-Whitney U test corrected for ties, and
Kruskal-Wallis analysis of variance respectively) – but as
these analyses did not differ, likely because TGFβ1 was
normally distributed, they are not reported. In order to
assess whether TGFβ1 serum concentrations were related
to length of disease and demographic factors, multiple
regression models were developed using a stepwise
approach. All analyses were carried out using Data Desk
6.2.l (Data Description, Ithaca, New York, 2003).
Results
Fifty-five patients in various sub-type groups (table 1)
were studied. The mean age (± SD) at disease onset was
9.2 ± 3.6 years, (range of 0.7 to 19.2 years, median 8.7
years). The mean disease duration at the time of TGFβ1
sampling was 4.9 ± 3.7 years.
The mean serum TGFβ1 concentrations were significantly
higher in patients than controls: 51393 ± 33953 pg/ml,
(range 2949 – 141965 pg/ml), vs. 9825 ± 5287 pg/ml
Table 1: Patient sub-groups
Patient Group Number of patients
M1 0
GM 16
LIN face 11
LIN limb 18Pediatric Rheumatology 2007, 5:22 http://www.ped-rheum.com/content/5/1/22
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(range 4725 – 16761 pg/ml) (p < 0.0001). There was no
significant difference between the TGFβ1 measurements
between the 4 different subtypes as described above (Fig
1). (Mean TGFβ1 for LIN face = 39991 pg/ml, GM =
49053 pg/ml, M = 55,939 pg/ml, LIN limb = 58,481 pg/
ml, F (3,51) = 0.714, p = 0.55.)
There was no difference in TGFβ1 serum concentrations
between the 21 patients in the active phase of the disease
(51374 pg/ml), to the 23 patients with inactive disease
(50985 pg/ml), or the 11 indeterminate phase patients
(52284 pg/ml); F (2,52) = 0.0053, p = 0.99 (Fig. 2).
In a multiple regression model, there was no significant
relationship between TGFβ1 serum concentrations and
patient demographics (age, disease duration) or basic lab-
oratory markers (ESR, eosinophil count, IgG concentra-
tions or ANA),
Discussion
Our study clearly demonstrates that serum concentratons
of TGFβ1 are very elevated in pediatric LS patients at all
times during evolution of their disease. The measure-
ments were elevated in all the disease subtypes, and there
was no correlation between the disease activity and the
cytokine levels. This is in accord with previous studies that
reported increased TGFβ1 serum concentrations in adults
with SSc and LS [4-6].
TGFβ1 mediates fibrosis through downstream modula-
tors. It is derived from many cellular sources including
members of the immune system and those in other organ
systems including activated endothelial cells. A critical
downstream effect is stimulation of fibroblasts and exces-
sive extra-cellular matrix deposition [3]. TGFβ1 is secreted
as a pro-peptide (latent form) and enzymatically cleaved
into the active form [8], and is a potent chemoattractant
for human skin fibroblasts [9]. TGFβ1 also up-regulates
TGFβ1 levels in LS and control groups Figure 1
TGFβ1 levels in LS and control groups. Peripheral blood concentrations of TGFβ1 (pg/ml) in the different sub-groups of 
patients with LS and in controls. In the box and whisker plots, the horizontal line in the middle of the box represents the 
median, the bottom and top of the box represent one standard deviation from the mean, and the lines (whiskers) represent 2 
standard deviations. Individual outlyers are represented by the circles above 2 SDs.Pediatric Rheumatology 2007, 5:22 http://www.ped-rheum.com/content/5/1/22
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synthesis of matrix metalloproteinase inhibitors, which
inhibit collagenase activity [10].
In our study, there was no correlation between the serum
concentrations of TGFβ1 and LS disease activity or disease
subtype. There has been much work regarding an appro-
priate classification system for localized scleroderma.
Interestingly, our data suggest that regardless of classifica-
tion system used, this is a cohesive group of patients with
elevation of circulating TGFβ1 as a common feature. Inter-
estingly, high levels were also found in all phases of the
disease included inactive states. Many different hypothe-
sis can be invoked to explain this finding including mod-
ulation at the receptor level [11], as increased expression
of TGFβ1 receptors are reported in skin fibroblasts of SSc
and LS patients [12-14] and continued production of
TGFβ1 by endothelial cells as a repair/wound healing
response in inactive lesions. Alternatively, immune
sources of TGFβ1 may be responsible for production of
TGFβ1 as a regulatory/counter-inflammatory cytokine
keeping the disease in the quiescent phase. Or it may sim-
ply by that peripheral blood levels of TGFβ1, a cytokine
known to affect changes locally in only limited areas of
affected skin, do not represent biochemical activity in
affected skin; a scenario common to cytokines and
enzymes which are tightly regulated at the tissue level.
Another practical explanation of the lack of correlation
between disease activity and TGFβ blood levels may be
related to our limited clinical ability to determine disease
activity accurately. It may be overly simplistic to assume a
direct relationship between TGFβ1 and disease, as with
other processes in the complex milieu of the human body,
multiple mechanisms are at play to regulate the balance
between extracellular matrix production and degradation.
Potential limitations of our study include population
selection, specifically our control population. Our control
group consisted of children with atopic dermatitis. LS is
an inflammatory skin disease as is atopic dermatitis, thus
making children with atopic dermatitis our choice for a
specificity control for non- specific inflammation of the
skin. Circulating levels of TGFβ1 in this population may
be different from levels in healthy children. In fact, some
reports suggest an association between low TGFβ1
responder genotype [15] and low TGFβ1 mRNA produc-
tion by circulating leukocytes in some children with
atopic dermatitis [16].
Conclusion
Increased TGFβ1 serum concentrations appear to be com-
mon to all subtypes of children with LS suggesting a
potentially useful role for TGFβ1 as a biomarker of the dis-
ease. Lack of correlation of circulating TGFβ1 concentra-
tion with disease activity preclude their use clinically to
guide therapy in affected children.
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